By expert opinion, HCC surveillance with abdominal US with or without serum AFP levels twice per year is recommended for patients with lean NAFLD and clinical indicators consistent with liver cirrhosis [159]. This evidence concerns the gene AFP and metabolic dysfunction-associated steatotic liver disease.